

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
9 November 2000 (09.11.2000)

PCT

(10) International Publication Number  
**WO 00/66096 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/19**,  
31/4015, 31/4166, 31/495, 31/55, 31/551, A61P 11/06

(21) International Application Number: PCT/GE00/00002

(22) International Filing Date: 28 April 2000 (28.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
A 1999 003512 30 April 1999 (30.04.1999) GE

(71) Applicant and

(72) Inventor: LOMIA, Merab [GE/GE]; Corp. 3, Apt. 7, 166  
Ambrolauri St., Tbilisi, 380060 (GE).

(81) Designated States (*national*): AE, AM, AT, AU, AZ, BG,  
BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE,

HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MA, MD, MK,  
MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA,  
US, UZ, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

Published:

— With international search report.

(88) Date of publication of the international search report:  
22 March 2001

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: USE OF ANTIEPILEPTICS FOR TREATING RESPIRATORY DISORDERS, IN PARTICULAR ASTHMATIC DISORDERS

(57) Abstract: This invention refers to medicine, in particular to pharmacology and pharmacotherapy. The technical result is to prevent specific expiratory bronchospasm in patients with bronchial asthma and other diseases and pathological conditions. The principally new indication provides use of antiepileptic agents for treatment of all types of bronchial asthma, status asthmaticus, asthmatic and allergic bronchitis, bronchial hyperreactivity and bronchospastic syndromes and treatment of diseases proceeding with these syndromes and also for treatment of allergic and vasomotor rhinitis and rhinoconjunctivitis.

WO 00/66096 A3